Geron Corporation
GERN
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.0B
$1.57
▲ +3.97%
P/E
-15.75
Mkt Cap
$1.0B
52-Wk Range
$1.04–$2.01
52-Week Range
$1.04 - $2.01
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 14.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- First-in-class telomerase inhibitor mechanism targeting cancer stem cells
- Advanced clinical development stage with Phase 3 trials underway
- Differentiated approach addressing root cause of hematologic malignancies rather than symptoms
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Moderate growth ahead
Positive Phase 3 clinical trial results for imetelstat in MDS and MF
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+38.9% over 3m
Quality
Excellent
High-growth business (24% revenue growth, 83% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying GERN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of -$0.02 vs -$0.01 consensus (-125.2% surprise). Revenue of $57.5M vs $55.3M expected (+3.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-125.2%
Revenue trend · last 8Q
—
—
—
—
+67%
+1%
+31%
+17%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$28.3M
$47.5M
$39.6M
$49.0M
$47.2M
$48.0M
$51.8M
$57.5M
Margins · last 8Q
Gross
0.0%
Operating
-21.7%
Profit
-29.0%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How GERN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related